Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort

PURPOSE: Advances in therapy of metastatic castration-refractory prostate cancer (mCRPC) resulted in more therapeutic options and led to a higher need of predictive/prognostic biomarkers. Systemic inflammatory biomarkers could provide the basis for personalized treatment selection. This study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Neuberger, Manuel, Goly, Nora, Skladny, Janina, Milczynski, Veronica, Weiß, Christel, Wessels, Frederik, Nitschke, Katja, Grüne, Britta, Haney, Caelán M., Hartung, Friedrich, Herrmann, Jonas, Jarczyk, Jonas, Kowalewski, Karl F., Waldbillig, Frank, Kriegmair, Maximilian C., Westhoff, Niklas, Worst, Thomas S., Nuhn, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314827/
https://www.ncbi.nlm.nih.gov/pubmed/35939112
http://dx.doi.org/10.1007/s00432-022-04220-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314827/
https://www.ncbi.nlm.nih.gov/pubmed/35939112
http://dx.doi.org/10.1007/s00432-022-04220-w

Ejemplares similares